Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 12.49 5.58% 0.66
DRNA closed up 5.58 percent on Friday, May 24, 2019, on 1.67 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical DRNA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Gapped Up Strength 0.00%
MACD Bullish Signal Line Cross Bullish 5.58%
NR7 Range Contraction 5.58%
Inside Day Range Contraction 5.58%
Down 3 Days in a Row Weakness 7.67%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.05%
NR7 Range Contraction 5.05%
Inside Day Range Contraction 5.05%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.78%

Older signals for DRNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Medicine Biopharmaceutical Cancer Diseases Disease Cancers Enzymes Paroxysmal Nocturnal Hemoglobinuria Liver Liver Diseases Carcinogenesis Cardiomyopathy Hemophilia A Ras Subfamily C Met Drug Delivery Technologies Familial Amyloid Polyneuropathy Hyperoxaluria Primary Hyperoxaluria Treatment Of Various Cancers Treatment Of Various Diseases
Is DRNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 17.98
52 Week Low 9.31
Average Volume 389,845
200-Day Moving Average 13.1172
50-Day Moving Average 13.3058
20-Day Moving Average 12.16
10-Day Moving Average 11.698
Average True Range 0.6627
ADX 23.94
+DI 25.0851
-DI 20.2858
Chandelier Exit (Long, 3 ATRs ) 11.8119
Chandelier Exit (Short, 3 ATRs ) 12.6881
Upper Bollinger Band 13.5301
Lower Bollinger Band 10.7899
Percent B (%b) 0.62
BandWidth 22.534539
MACD Line -0.3847
MACD Signal Line -0.4589
MACD Histogram 0.0742
Fundamentals Value
Market Cap 260.35 Million
Num Shares 20.8 Million
EPS -3.20
Price-to-Earnings (P/E) Ratio -3.90
Price-to-Sales 155.10
Price-to-Book 7.93
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.50
Resistance 3 (R3) 13.44 13.06 13.33
Resistance 2 (R2) 13.06 12.80 13.08 13.27
Resistance 1 (R1) 12.77 12.64 12.92 12.83 13.22
Pivot Point 12.39 12.39 12.46 12.41 12.39
Support 1 (S1) 12.10 12.13 12.25 12.16 11.76
Support 2 (S2) 11.72 11.97 11.74 11.71
Support 3 (S3) 11.43 11.72 11.65
Support 4 (S4) 11.49